Semaglutide
Product Name
Semaglutide
Quick Details
Pro Name: Semaglutide
CasNo:910463-68-2
Molecular Formula: C187h291n45o59
Indication
Semaglutide is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
Semaglutide has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Semaglutide is not a substitute for insulin. Semaglutide is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.
© 2021 Hybio Pharma. All Rights Reserved.
Peptide Products & Services
About us
Newsroom
Follow us